- Home
- TEM vs VTRS Comparison
TEM vs VTRS Comparison
Compare TEM & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEM
- VTRS
- Stock Information
- Founded
- TEM 2015
- VTRS 1961
- Country
- TEM United States
- VTRS United States
- Employees
- TEM N/A
- VTRS N/A
- Industry
- TEM
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- TEM
- VTRS Health Care
- Exchange
- TEM NYSE
- VTRS Nasdaq
- Market Cap
- TEM 11.9B
- VTRS 10.6B
- IPO Year
- TEM 2024
- VTRS N/A
- Fundamental
- Price
- TEM $58.41
- VTRS $9.24
- Analyst Decision
- TEM Buy
- VTRS Hold
- Analyst Count
- TEM 12
- VTRS 5
- Target Price
- TEM $65.09
- VTRS $10.40
- AVG Volume (30 Days)
- TEM 10.1M
- VTRS 11.3M
- Earning Date
- TEM 08-05-2025
- VTRS 08-07-2025
- Dividend Yield
- TEM N/A
- VTRS 5.18%
- EPS Growth
- TEM N/A
- VTRS N/A
- EPS
- TEM N/A
- VTRS N/A
- Revenue
- TEM $803,315,000.00
- VTRS $14,330,200,000.00
- Revenue This Year
- TEM $81.57
- VTRS N/A
- Revenue Next Year
- TEM $24.86
- VTRS $1.85
- P/E Ratio
- TEM N/A
- VTRS N/A
- Revenue Growth
- TEM 42.93
- VTRS N/A
- 52 Week Low
- TEM $30.81
- VTRS $6.85
- 52 Week High
- TEM $91.45
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- TEM N/A
- VTRS 59.52
- Support Level
- TEM N/A
- VTRS $9.17
- Resistance Level
- TEM N/A
- VTRS $9.42
- Average True Range (ATR)
- TEM 0.00
- VTRS 0.21
- MACD
- TEM 0.00
- VTRS 0.02
- Stochastic Oscillator
- TEM 0.00
- VTRS 79.61
About TEM TEMPUS AI INC
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.